{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:06:50Z","timestamp":1777446410813,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":3065,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.jacc.2005.01.014","type":"journal-article","created":{"date-parts":[[2005,4,15]],"date-time":"2005-04-15T07:25:02Z","timestamp":1113549902000},"page":"1249-1250","source":"Crossref","is-referenced-by-count":9,"title":["Should we consider aldosterone as the primary screening target for preventing cardiovascular events?**Editorials published in the Journal of American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology."],"prefix":"10.1016","volume":"45","author":[{"given":"Gary S.","family":"Francis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2005.01.014_bib1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/01.ASN.0000132473.50966.14","article-title":"Mechanisms of hypertension","volume":"15","author":"Freel","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2005.01.014_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2005.01.014_bib3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2005.01.014_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone- and angiotensin II-induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2005.01.014_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2005.01.014_bib6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","article-title":"Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment","volume":"90","author":"Macdonald","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2005.01.014_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","article-title":"Essential hypertension","volume":"286","author":"Brunner","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2005.01.014_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mce.2003.10.006","article-title":"Primary aldosteronism\u2014careful investigation is essential and rewarding","volume":"217","author":"Stowasser","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2005.01.014_bib9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2005.01.014_bib10","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","article-title":"Remodeling of the left ventricle in primary aldosteronism due to Conn\u2019s adenoma","volume":"95","author":"Rossi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2005.01.014_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2005.01.014_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1440-1681.2001.03523.x","article-title":"New perspectives on the role of aldosterone excess in cardiovascular disease","volume":"28","author":"Stowasser","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jacc.2005.01.014_bib13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2005.01.014_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2005.01.014_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0735-1097(02)02695-5","article-title":"Spironolactone in chronic heart failure","volume":"41","author":"Tang","year":"2003","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109705002172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109705002172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T04:21:05Z","timestamp":1548562865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109705002172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0735109705002172"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2005.01.014","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}